Dosiomics-Based Prediction of Radiation-Induced Valvulopathy after Childhood Cancer.
childhood cancer
dosimetry
dosiomics
imbalanced classification
late effects
radiotherapy
random forest
valvulopathy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Jun 2023
08 Jun 2023
Historique:
received:
01
03
2023
revised:
16
05
2023
accepted:
05
06
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Valvular Heart Disease (VHD) is a known late complication of radiotherapy for childhood cancer (CC), and identifying high-risk survivors correctly remains a challenge. This paper focuses on the distribution of the radiation dose absorbed by heart tissues. We propose that a dosiomics signature could provide insight into the spatial characteristics of the heart dose associated with a VHD, beyond the already-established risk induced by high doses. We analyzed data from the 7670 survivors of the French Childhood Cancer Survivors' Study (FCCSS), 3902 of whom were treated with radiotherapy. In all, 63 (1.6%) survivors that had been treated with radiotherapy experienced a VHD, and 57 of them had heterogeneous heart doses. From the heart-dose distribution of each survivor, we extracted 93 first-order and spatial dosiomics features. We trained random forest algorithms adapted for imbalanced classification and evaluated their predictive performance compared to the performance of standard mean heart dose (MHD)-based models. Sensitivity analyses were also conducted for sub-populations of survivors with spatially heterogeneous heart doses. Our results suggest that MHD and dosiomics-based models performed equally well globally in our cohort and that, when considering the sub-population having received a spatially heterogeneous dose distribution, the predictive capability of the models is significantly improved by the use of the dosiomics features. If these findings are further validated, the dosiomics signature may be incorporated into machine learning algorithms for radiation-induced VHD risk assessment and, in turn, into the personalized refinement of follow-up guidelines.
Identifiants
pubmed: 37370717
pii: cancers15123107
doi: 10.3390/cancers15123107
pmc: PMC10296033
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Radiat Oncol Biol Phys. 2023 Apr 1;115(5):1291-1300
pubmed: 36462689
J Radiol Prot. 2017 Mar 20;37(1):R1-R18
pubmed: 28118156
Eur Heart J Cardiovasc Imaging. 2022 Sep 10;23(10):e333-e465
pubmed: 36017575
Clin Oncol (R Coll Radiol). 2022 Feb;34(2):e87-e96
pubmed: 34924256
Radiother Oncol. 2021 Oct;163:199-208
pubmed: 34454975
Radiother Oncol. 2011 Nov;101(2):316-21
pubmed: 21925755
Front Oncol. 2019 Apr 12;9:269
pubmed: 31032229
CA Cancer J Clin. 2021 Jul;71(4):315-332
pubmed: 33793968
J Am Soc Echocardiogr. 2021 Feb;34(2):107-116
pubmed: 33223357
J Natl Cancer Inst. 2015 Feb 23;107(4):
pubmed: 25713164
Swiss Med Wkly. 2019 Mar 10;149:w20012
pubmed: 30852834
Front Oncol. 2021 Sep 16;11:679701
pubmed: 34604027
Radiat Oncol. 2018 Sep 24;13(1):187
pubmed: 30249274
Radiother Oncol. 1996 Mar;38(3):269-71
pubmed: 8693110
Cancers (Basel). 2021 Jul 30;13(15):
pubmed: 34359737
J Clin Oncol. 2018 Jul 20;36(21):2216-2222
pubmed: 29874139
Cancer Epidemiol Biomarkers Prev. 2021 Jan;30(1):133-141
pubmed: 33033142
Eur J Heart Fail. 2019 Apr;21(4):509-518
pubmed: 30592114
Eur J Cancer. 2010 Apr;46(6):1069-78
pubmed: 20171084
Front Cardiovasc Med. 2018 Jul 09;5:83
pubmed: 30038908
JACC CardioOncol. 2020 Sep 15;2(3):363-378
pubmed: 34396245
Circulation. 2016 Jan 5;133(1):31-8
pubmed: 26487757
JCO Clin Cancer Inform. 2021 Apr;5:459-468
pubmed: 33909450
Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):213-22
pubmed: 25442333
Nature. 2020 Sep;585(7825):357-362
pubmed: 32939066
Blood. 2011 Jan 13;117(2):412-8
pubmed: 20858859
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1216-24
pubmed: 25442047
Acta Oncol. 2015 Nov;54(10):1796-804
pubmed: 25800857
Heart. 2016 Feb 15;102(4):269-76
pubmed: 26661320
Radiat Oncol. 2019 Sep 2;14(1):157
pubmed: 31477141
BMC Med Inform Decis Mak. 2022 Oct 17;22(1):270
pubmed: 36253749
Oral Oncol. 2020 May;104:104625
pubmed: 32151995
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
Pediatr Blood Cancer. 2010 Dec 1;55(6):1145-52
pubmed: 20734400
Pediatr Blood Cancer. 2019 Feb;66(2):e27495
pubmed: 30345604
Front Oncol. 2020 Jun 05;10:790
pubmed: 32582539
Cardiooncology. 2022 Apr 8;8(1):7
pubmed: 35395814
BMJ. 2020 Jan 15;368:l6794
pubmed: 31941657
Phys Med. 2021 Sep;89:219-225
pubmed: 34425512
Radiother Oncol. 2023 Mar;180:109479
pubmed: 36657724
Int J Radiat Oncol Biol Phys. 2022 Jan 1;112(1):247-259
pubmed: 34706278
J Clin Oncol. 2019 May 1;37(13):1090-1101
pubmed: 30860946
Radiat Oncol. 2018 Jul 3;13(1):122
pubmed: 29970105
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):e151-5
pubmed: 23273995